Teva stock names interim R&D lead as chief medical officer exits
Published on 11/19/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSR&D leadership changes at Teva
- David Gardiner will lead Teva's R&D organization during the search for a permanent successor.
- The company reiterated its ambition to generate US$6 billion to US$7 billion in innovative-medicines revenue by 2030.
- Teva said its R&D strategy, priorities and expectations remain unchanged.
Teva Pharmaceutical Industries said on Wednesday, November 18, 2026, that Eric Hughes, its executive vice president for global research and development and chief medical officer, will leave the company after accepting an offer outside Teva. The announcement was made in a Teva press release.
Interim leadership for R&D
David Gardiner, head of innovative medicines and clinical development, will serve as transition lead for R&D with immediate effect. He will report directly to President and Chief Executive Officer Richard Francis while Teva searches for a permanent successor.
Hughes will remain with Teva for the coming months to support the transition. He helped build the pipeline and organizational structure presented at the company's R&D Day, Teva said.
Pipeline plans remain in place
Teva said the leadership change does not alter its R&D strategy, priorities or expectations. The company reiterated its ambition to generate US$6 billion to US$7 billion in innovative-medicines revenue by 2030, following the commitments presented at its November 11 R&D Day.
For investors, the transition puts emphasis on continuity as Teva advances its neuroscience and immunology pipeline while maintaining its generics, complex-generics and biosimilars businesses. The search for a permanent R&D leader now becomes a further execution milestone for the growth strategy.
Teva Pharmaceutical Industries
- Company: Teva Pharmaceutical Industries Ltd.
- Ticker: TEVA
- Listings: New York Stock Exchange and Tel Aviv Stock Exchange
- Leadership change: David Gardiner leads R&D during the successor search
The broader Israeli market is represented by the TA-35.
